Anti-facteur de croissance nerveuse (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Anti-facteur de croissance nerveuse" in French language version.

refsWebsite

Global rank French rank

2^nd place

3^rd place

4^th place

12^th place

57^th place

4^th place

11^th place

325^th place

1,523^rd place

2,842^nd place

low place

doi.org

(en) Oo et Hunter, « Nerve Growth Factor (NGF) Inhibitors and Related Agents for Chronic Musculoskeletal Pain: A Comprehensive Review », BioDrugs, vol. 35, n^o 6,‎ 1^er novembre 2021, p. 611–641 (ISSN 1179-190X, PMID 34807432, DOI 10.1007/s40259-021-00504-8, S2CID 244509341, lire en ligne)
« The evolution of nerve growth factor inhibition in clinical medicine », Nature Reviews. Rheumatology, vol. 17, n^o 1,‎ janvier 2021, p. 34–46 (PMID 33219344, DOI 10.1038/s41584-020-00528-4, S2CID 227065883, lire en ligne)
« Targeting nerve growth factor, a new option for treatment of osteoarthritis: a network meta-analysis of comparative efficacy and safety with traditional drugs », Aging, vol. 13, n^o 1,‎ décembre 2020, p. 1051–1070 (PMID 33293475, PMCID 7835067, DOI 10.18632/aging.202232)
« Diagnosis and Treatment of Hip and Knee Osteoarthritis: A Review », JAMA, vol. 325, n^o 6,‎ février 2021, p. 568–578 (ISSN 0098-7484, PMID 33560326, PMCID 8225295, DOI 10.1001/jama.2020.22171)
« Anti-nerve growth factor in pain management: current evidence », Journal of Pain Research, vol. 9,‎ 8 juin 2016, p. 373–83 (PMID 27354823, PMCID 4908933, DOI 10.2147/JPR.S89061)
« Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety », Pain, vol. 160, n^o 10,‎ octobre 2019, p. 2210–2220 (PMID 31145219, PMCID 6756297, DOI 10.1097/j.pain.0000000000001625)

(en) Oo et Hunter, « Nerve Growth Factor (NGF) Inhibitors and Related Agents for Chronic Musculoskeletal Pain: A Comprehensive Review », BioDrugs, vol. 35, n^o 6,‎ 1^er novembre 2021, p. 611–641 (ISSN 1179-190X, PMID 34807432, DOI 10.1007/s40259-021-00504-8, S2CID 244509341, lire en ligne)

« The evolution of nerve growth factor inhibition in clinical medicine », Nature Reviews. Rheumatology, vol. 17, n^o 1,‎ janvier 2021, p. 34–46 (PMID 33219344, DOI 10.1038/s41584-020-00528-4, S2CID 227065883, lire en ligne)

(en) Oo et Hunter, « Nerve Growth Factor (NGF) Inhibitors and Related Agents for Chronic Musculoskeletal Pain: A Comprehensive Review », BioDrugs, vol. 35, n^o 6,‎ 1^er novembre 2021, p. 611–641 (ISSN 1179-190X, PMID 34807432, DOI 10.1007/s40259-021-00504-8, S2CID 244509341, lire en ligne)
« Diagnosis and Treatment of Hip and Knee Osteoarthritis: A Review », JAMA, vol. 325, n^o 6,‎ février 2021, p. 568–578 (ISSN 0098-7484, PMID 33560326, PMCID 8225295, DOI 10.1001/jama.2020.22171)

(en) Oo et Hunter, « Nerve Growth Factor (NGF) Inhibitors and Related Agents for Chronic Musculoskeletal Pain: A Comprehensive Review », BioDrugs, vol. 35, n^o 6,‎ 1^er novembre 2021, p. 611–641 (ISSN 1179-190X, PMID 34807432, DOI 10.1007/s40259-021-00504-8, S2CID 244509341, lire en ligne)
« The evolution of nerve growth factor inhibition in clinical medicine », Nature Reviews. Rheumatology, vol. 17, n^o 1,‎ janvier 2021, p. 34–46 (PMID 33219344, DOI 10.1038/s41584-020-00528-4, S2CID 227065883, lire en ligne)
« Targeting nerve growth factor, a new option for treatment of osteoarthritis: a network meta-analysis of comparative efficacy and safety with traditional drugs », Aging, vol. 13, n^o 1,‎ décembre 2020, p. 1051–1070 (PMID 33293475, PMCID 7835067, DOI 10.18632/aging.202232)
« Diagnosis and Treatment of Hip and Knee Osteoarthritis: A Review », JAMA, vol. 325, n^o 6,‎ février 2021, p. 568–578 (ISSN 0098-7484, PMID 33560326, PMCID 8225295, DOI 10.1001/jama.2020.22171)
« Anti-nerve growth factor in pain management: current evidence », Journal of Pain Research, vol. 9,‎ 8 juin 2016, p. 373–83 (PMID 27354823, PMCID 4908933, DOI 10.2147/JPR.S89061)
« Nerve growth factor antibody for the treatment of osteoarthritis pain and chronic low-back pain: mechanism of action in the context of efficacy and safety », Pain, vol. 160, n^o 10,‎ octobre 2019, p. 2210–2220 (PMID 31145219, PMCID 6756297, DOI 10.1097/j.pain.0000000000001625)

(en) Oo et Hunter, « Nerve Growth Factor (NGF) Inhibitors and Related Agents for Chronic Musculoskeletal Pain: A Comprehensive Review », BioDrugs, vol. 35, n^o 6,‎ 1^er novembre 2021, p. 611–641 (ISSN 1179-190X, PMID 34807432, DOI 10.1007/s40259-021-00504-8, S2CID 244509341, lire en ligne)
« The evolution of nerve growth factor inhibition in clinical medicine », Nature Reviews. Rheumatology, vol. 17, n^o 1,‎ janvier 2021, p. 34–46 (PMID 33219344, DOI 10.1038/s41584-020-00528-4, S2CID 227065883, lire en ligne)

(en) Paul Imrie, « Zoetis announces monoclonal antibody therapies for OA », sur vettimes.co.uk, 13 avril 2021 (consulté le 18 octobre 2023)